This is supported by a recent study implicating Emp2 in a maladaptive pathway of vSMC proliferation in diabetic rats and raises the possibility of targeting EMP2 for the treatment of vasculo-proliferative diseases in diabetes (38). The gene discussed is EMP2; the disease is diabetes mellitus.